Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Total Debt

Last Annual Value

2.34M

3-Year CAGR

-6%

5-Year CAGR

-23%

10-Year CAGR

-13%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Total Debt

SERA · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.34M
8.0%78.8%N/A 
23.87M
48.1%N/AN/A
39.34M
0.7%164.3%29.0%
112.06K
N/AN/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
29.18M
-14.4%12.1%N/A
13.42M
-5.7%N/AN/A
3.50M
6.8%-9.2%21.2%
1.51M
-17.7%-16.5%35.6%
288.02M
33.8%50.0%80.1%
25.82B
1091.7%N/AN/A
502.67K
-40.2%-4.8%N/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245